Login to Your Account

Other News To Note

Wednesday, January 5, 2011

Celgene International Sàrl, of Boudry, Switzerland, submitted a marketing authorization application for the approval of Revlimid (lenalidomide) as a maintenance treatment for newly diagnosed multiple myeloma patients who have not progressed following initial treatment with melphalan, prednisone and Revlimid, or following autologous stem cell transplantation.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription